The adverse changes in gut microbiome, intestinal low-grade inflammation, and oxidative stress in IBS may lead to visceral adipose tissue dysfunction manifested by an imbalance between pro-inflammatory (e.g., chemerin) and anti-inflammatory (e.g., omentin-1) adipokines. Here, RARRES2 is linked to irritable bowel syndrome.